Best Danyelza (Naxitamab) Medicine in India

Danyelza (Naxitamab) is a targeted anticancer treatment used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children aged 1 year and older and adults with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have shown a partial response, minor response, or stable disease to prior treatment. It is a monoclonal antibody that targets GD2, a protein commonly found on neuroblastoma cells.

Danyelza (Naxitamab) is administered as an intravenous infusion by a qualified healthcare professional. It is usually given according to a scheduled treatment cycle and requires premedication and close monitoring because infusion-related reactions and pain can occur during treatment. Your doctor may monitor blood pressure, heart rate, oxygen levels, and other vital signs during and after the infusion.

Common side effects of Danyelza (Naxitamab) may include pain, fever, increased heart rate, vomiting, nausea, cough, headache, high blood pressure, and infusion-related reactions. Serious reactions can include severe pain, allergic or infusion reactions, nerve-related problems, and high blood pressure. Inform your healthcare team immediately if you develop difficulty breathing, swelling, severe pain, dizziness, or other unusual symptoms during or after the infusion.

Treatment of High-Risk Neuroblastoma

Danyelza (Naxitamab) is used with GM-CSF to treat certain patients with relapsed or refractory high-risk neuroblastoma involving the bone or bone marrow. It targets GD2 proteins on neuroblastoma cells and helps the immune system recognize and destroy these abnormal cells, helping to control disease progression.

Most side effects do not require medical attention and may improve as your body adjusts to the treatment. Consult your doctor if they persist, become severe, or cause concern.

Common Side Effects of Danyelza (Naxitamab)

Danyelza (Naxitamab) is given as an intravenous infusion by a qualified healthcare professional in combination with GM-CSF. Treatment is administered according to the schedule prescribed by your doctor. Pain-relieving medicines and other premedications may be given before and during treatment to reduce infusion-related reactions and pain. Blood pressure, heart rate, oxygen levels, and other vital signs are closely monitored during and after the infusion.

Danyelza (Naxitamab) is a monoclonal antibody that targets GD2, a protein found on the surface of neuroblastoma cells. By binding to GD2, it helps activate the immune system to recognize and destroy cancer cells, helping to control the growth and progression of high-risk neuroblastoma.

• Store the unopened vial in a refrigerator between 2°C and 8°C.
• Do not freeze, and keep the vial in its original carton to protect it from light.
• After dilution, use the infusion solution within 8 hours when stored at room temperature.
• If refrigerated at 2°C to 8°C, use the diluted solution within 24 hours and keep it out of the reach of children.

Alcohol CONSULT YOUR DOCTOR

Avoid or limit alcohol during treatment, as it may worsen dizziness, fatigue, or other treatment-related side effects. Consult your doctor for personalized advice.

Pregnancy CONSULT YOUR DOCTOR

Danyelza (Naxitamab) may harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for the period advised by their doctor.

Breastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment with Danyelza (Naxitamab) and for the period recommended by your doctor.

Driving CONSULT YOUR DOCTOR

Danyelza (Naxitamab) may cause dizziness, fatigue, or other effects that can affect alertness. Avoid driving or operating machinery if you feel affected.

Kidney CAUTION

Inform your doctor if you have kidney problems. Your kidney function may be monitored during treatment as advised by your healthcare team.

Liver CAUTION

Tell your doctor about any liver problems before treatment. Your doctor may monitor liver function during treatment.

• Attend all scheduled Danyelza (Naxitamab) infusions and follow your treatment schedule carefully.
• Take prescribed premedications as directed to help reduce pain and infusion-related reactions.
• Inform your healthcare team immediately about breathing difficulties, severe pain, dizziness, or swelling during or after infusion.
• Attend regular check-ups and monitoring of blood pressure, heart rate, and other vital signs.
• Report fever, unusual weakness, persistent vomiting, or other new or worsening symptoms promptly.
• Read More About - Danyelza (Naxitamab) from Pharma Five.

Pharma Five, may facilitate patients in importing Danyelza (Naxitamab) in small quantities for personal medical use. To facilitate the import process, the applicant is required to submit an application in Form 12A along with a prescription issued by a Registered Medical Practitioner (RMP).

Pharma Five has extensive experience in pharmaceutical consultancy and facilitates patient access to Danyelza (Naxitamab) and other specialized medicines through professional import-related services. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.